Headquartered in New York, NY Fiscal year ends December NYSE: PFE pfizer.com
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. The company operates primarily through its Global Biopharmaceuticals Business (Biopharma) segment and Pfizer CentreOne contract manufacturing division. Its commercial structure includes the Pfizer U.S. Commercial Division, the Pfizer International Commercial Division, and the Global Hospital and Biosimilars Division. Pfizer's portfolio spans primary care (including Eliquis for blood clots, the Prevnar pneumococcal vaccine family, Comirnaty COVID-19 vaccine, Paxlovid antiviral, and Abrysvo RSV vaccine), oncology (including Ibrance for breast cancer, Padcev for urothelial and bladder cancer, Xtandi for prostate cancer, Lorbrena for ALK+ lung cancer, and several other targeted therapies), and specialty care (including the Vyndaqel family for transthyretin amyloid cardiomyopathy, Xeljanz, and Cibinqo). The company also markets biosimilars and operates a contract manufacturing business. Pfizer has a robust late-stage pipeline including berobenatide, a potential first-in-class monthly GLP-1 receptor agonist for obesity, a 25-valent pneumococcal conjugate vaccine candidate, and sigvotatug vedotin in multiple oncology settings. Pfizer recently entered a strategic licensing and collaboration agreement with Innovent Biologics for 12 early-stage cancer medicines including antibody-drug conjugates and multi-specific antibodies. Updated
Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.
Pfizer just marked a fresh 52-week high at $29.02, 1.58% above the peak it set on Aug. 25. Anyone anchored to the low-$23 range from a year ago is now looking at a very different reference point.
Seven names printed fresh 52-week highs this week, spanning travel, software and defensives. Box led with a 3.98% clearance over its prior peak, with Coca-Cola, Pfizer, Airbnb and Expedia also at new records.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
Pfizer closed at $28.24, a new 52-week high that clears the April 1 peak. The drugmaker has now taken out the ceiling that capped it all spring, making that old level the line to defend.
A retiree living off a portfolio needs income that keeps coming. The First Trust Morningstar Dividend Leaders Index Fund (NYSEARCA:FDL) has paid distributions four times a year since 2006. FDL tracks Morningstar’s…
The capital required to collect over $108,000 a year in dividends without selling a share swings by more than $2 million depending on one decision you make before buying anything.
Four of these five large-cap dividend stocks just dropped sharply, pushing their yields above 6%, but a rising yield can signal opportunity or a warning sign depending on what sits beneath the…
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported…
Six high-yield dividend stocks can quietly hand the IRS thousands of dollars every single year, but where you hold them changes everything. The bracket you sit in determines exactly how much you…
Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ones can actually keep the checks…
Holding high-yield dividend stocks outside a Roth quietly drains thousands of dollars every year, and the losses compound in a way most investors never calculate until it is too late.
Four household names are paying dividend yields above 5%, but their earnings, cash flow, and balance sheets tell a different story than their press releases. Before you count on those checks arriving,…
Kraft Heinz, Pfizer, Verizon, and Dow all flash yields above 4%, but behind each payout sits a mix of impairments, rising debt, and shrinking sales that could turn a tempting income stream…
Six dividend stocks in a $500,000 portfolio sound like a solid income plan, but where you hold them decides how much of that income you actually keep, and the difference compounds into…
Retirees chasing income face a choice that looks simple on paper but hides a tax trap, a reinvestment problem, and a dividend cut risk that most income comparisons never mention.
A portfolio built entirely around stocks and equity funds can generate $12,300 a month, or $147,600 a year, in income. The no-bond design stands out with the 10-year Treasury yielding 5.2%. Using…
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine…
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide.
24/7 Wall St.'s 12-month price target for PFE is $34.04, rated Buy. The Wall Street consensus target is $29.26. PFE price prediction →
